C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

• Namrata S. Patil ,

  Roles Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing

  * E-mail: Namrata@gene.com

  Affiliation Genentech, S. San Francisco, California, United States of America

  https://orcid.org/0000-0001-6156-684X

  ⨯
• Wei Zou,

  Roles Formal analysis

  Affiliation Genentech, S. San Francisco, California, United States of America

  ⨯
• Simonetta Mocci,

  Roles Writing – review & editing

  Affiliation Genentech, S. San Francisco, California, United States of America

  ⨯
• Alan Sandler,

  Roles Writing – review & editing

  Affiliation Genentech, S. San Francisco, California, United States of America

  ⨯
• Marcus Ballinger,

  Roles Writing – review & editing

  Affiliation Genentech, S. San Francisco, California, United States of America

  ⨯
• Susan Flynn,

  Roles Project administration

  Affiliation Genentech, S. San Francisco, California, United States of America

  ⨯
• Marcin Kowanetz,

  Roles Conceptualization

  Current address: Bolt Therapeutics, California, United States of America

  Affiliation Genentech, S. San Francisco, California, United States of America

  ⨯
• Priti S. Hegde

  Roles Conceptualization, Writing – review & editing

  Current address: Foundation Medicine, Cambridge, Massachusetts, United States of America

  Affiliation Genentech, S. San Francisco, California, United States of America

  ⨯